P7C3

P7C3, 1-(3,6-dibromocarbazol-9-yl)-3-(phenylamino)propan-2-ol, is a synthetic aminopropyl carbazole identified through an unbiased, target-agnostic in vivo screen of approximately 1,000 small molecules for enhancers of adult hippocampal neurogenesis in living mice. The compound emerged from pool 7, compound 3 of that library, designated P7C3, and was reported by Pieper et al. in Cell (2010) as a proneurogenic and neuroprotective agent with high oral bioavailability, blood-brain barrier penetration, and a favorable toxicity profile at supratherapeutic doses [1]. Subsequent medicinal chemistry optimization produced two principal derivatives: P7C3-A20, a fluorinated analog approximately ten-fold more potent than the parent compound, and (minus)-P7C3-S243, an enantiopure aminopyridine variant with further improved druglike properties including near-equal brain-to-plasma partitioning and metabolic stability [2, 3].

The molecular target of P7C3 was identified in 2014 by Wang et al. as nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway [4]. Active P7C3 variants bind NAMPT, enhance its enzymatic activity, and restore intracellular NAD+ levels depleted by cytotoxic stress. The structure-activity relationship across 168 derivatives demonstrated a statistically exceptional concordance (p = 9.4 x 10 to the negative 20) between NAMPT binding competition and cytoprotective efficacy, and a similarly tight correlation (p = 1.8 x 10 to the negative 35) between doxorubicin protection and NAD+ restoration, establishing NAMPT activation as the primary pharmacological mechanism [4]. The neuroprotective consequence of enhanced NAD+ flux operates through SIRT1 signaling cascades, anti-apoptotic pathways, mitochondrial integrity, and suppression of neuroinflammation.

Preclinical efficacy has been demonstrated across a broad range of neurodegenerative and neuroinjury models. In the MPTP mouse model of Parkinson disease, P7C3-A20 at 10 mg/kg produced near-complete rescue of substantia nigra dopaminergic neurons with preservation of striatal dopaminergic projections [5]. In the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis, P7C3-A20 at 20 mg/kg maintained higher spinal motor neuron density at all time points and preserved motor function on accelerating rotarod [2]. In fluid percussion and controlled cortical impact models of traumatic brain injury, P7C3-A20 at 10 mg/kg in the published literature reduced contusion volume, increased neurogenesis, preserved long-term potentiation, and restored spatial memory [6, 7]. Remarkably, P7C3-A20 administered one year after traumatic brain injury in mice repaired blood-brain barrier structure, arrested chronic neurodegeneration, and restored cognitive function [8]. In the 5xFAD transgenic mouse model of Alzheimer disease, P7C3-A20 reversed tau phosphorylation, blood-brain barrier deterioration, oxidative stress, neuroinflammation, and cognitive impairment even when treatment was initiated at advanced disease stages, with normalization of the clinical biomarker p-tau217 in plasma [9]. In a nine-month oral dosing study in rhesus macaques at 10 mg/kg, P7C3-A20 produced robust hippocampal neuroprotection (three-fold increase in surviving BrdU-labeled neurons versus controls) with no microscopic evidence of toxicity across more than forty examined tissue types [10].

The compound has not entered human clinical trials. The preclinical safety pharmacology is favorable: neither P7C3-A20 nor (minus)-P7C3-S243 inhibits the hERG channel (IC50 greater than 10 micromolar), and both have been administered at high doses for extended periods without behavioral, weight, or histological adverse effects in rodents and nonhuman primates [2, 3, 10]. The pharmacokinetic profile includes 32 percent oral bioavailability, a half-life of approximately 6.7 hours after intraperitoneal administration, and brain penetration sufficient for central pharmacological activity [2, 11]. P7C3 and its derivatives are available as research-grade compounds from multiple chemical suppliers at greater than 95 percent purity. This monograph reviews the chemistry, synthesis, and structure-activity relationships of the P7C3 class; the NAMPT-NAD+ molecular pharmacology; the comprehensive preclinical pharmacology across neurodegenerative, neuroinjury, and neuropsychiatric models; pharmacokinetics and routes of administration; sourcing, reconstitution, and handling; stack-interaction considerations; the adverse-event and safety signal; and a comparative assessment of five neuroprotective or NAD+-modulating candidates against P7C3 on five competency standards.